Public Health and Research News

MIAMI, FL–(Marketwire – September 22, 2010) –  Simulated Environment Concepts (PINKSHEETS: SMEV) a/k/a SE Concepts, manufacturer and developer of medical, aesthetic and wellness equipment, announced that the Dermscan Group is close to wrapping up its clinical trial research on the SpaCapsule and the equipment’s medical benefits.

Dr. Ella Frenkel, Chairman and CEO of Simulated Environment Concepts, Inc. said, “SE Concepts tirelessly strives to develop products which return dividends to our customers by way of overall improved health. The Spa Capsule does just that. In allowing users to not only feel de-stressed and refreshed after each therapeutic session, but internally renewed, we’re able to deliver a product to the medical and wellness community that simply pays for itself.”

The international cosmetic and clinical research company, Dermscan, began its study during late spring of this year with an expected completion time of early to late October 2010. Due to the great emphasis on weight loss, cellulite reduction and therapeutic use in Europe, Dermscan took to task proving just a few of the medical benefits derived from using the SpaCapsule. Results of the study are anticipated to lend to the increasing international appeal of the SpaCapsule — possibly doubling its current global distribution commitment.

Dr. Ilya Spivak, Marketing Director and co-inventor of the SpaCapsule stated, “From this study we deduce that the Spa Capsule will continue to grow as a medical apparatus that is a ‘must have’ by the physical therapy, rehabilitation and pain management community. Being a doctor myself, many times I’ve witnessed the reversing affects that the Spa Capsule has on ailments. Frankly, it is quite amazing.”

Sources close to SE Concepts say the company is receiving much international fan fare from the incredible results achieved by those continuously using the Spa Capsule. It is strongly believed a positive reporting from Dermscan will continue to fuel the current growth of the product within the medical and wellness industries worldwide.

About Simulated Environment Concepts, Inc.

Simulated Environment Concepts, Inc. is the developer of a variety of products for wellness, relaxation, weight loss, and rehabilitation. Our aqua massage and hydromassage products are used by Doctors, Gyms, Spas, retail locations, offices, and many other venues. Incorporating oxygen, aromatherapy, massage, and even music or video from an iPod or an iPhone, our products deliver consistent results and excellent earning potential for businesses. For more information on Simulated Environment Concepts and its flagship product, SpaCapsule®, PTjetCapsule™, and Celude Laboratories™ products you can visit the company’s product website at www.spacapsule.com, the corporate website at www.seccorporation.com, or request more information via email at [email protected], or call at (888) 757-0797 or (305) 651-9200.

Safe Harbor

Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.

Click here to see all recent news from this company

MONTRÉAL, QUÉBEC–(Marketwire – 21 sept. 2010) – L’Hôpital général juif et Aurora Interactive Ltd., tous deux de Montréal, au Québec, ont annoncé aujourd’hui la signature d’un important contrat de vente. L’entente de trois ans permettra l’intégration de la plate-forme de communication numérique et visualiseur mScope éducation d’Aurora et le partage d’images cliniques à l’Hôpital général juif, un grand hôpital universitaire affilié à l’Université McGill. L’hôpital a l’intention d’utiliser les logiciels mScope pour créer un réseau d’éducation en ligne unique pour la recherche en pathologie.

Le projet sera dirigé par le Dr Alan Spatz, directeur du Département de pathologie de l’Hôpital général juif, chercheur principal à l’Institut Lady Davis de recherches médicales, et professeur de pathologie et d’oncologie à l’Université McGill. Il est également co-directeur du Programme intégré de recherche et de formation en cancer à l’Université McGill et titulaire de la Chaire de recherche du Canada sur la pathologie moléculaire.

« Avec cette entente, l’Université McGill et l’Hôpital général juif ont acquis la seule plate-forme numérique qui nous permettra d’atteindre nos objectifs ambitieux», a déclaré le Dr Spatz. « La fusion de notre expertise unique et des produits d’Aurora nous permettent d’offrir à nos étudiants la meilleure éducation de pathologie en ligne disponible. »

« Aurora est heureux de s’associer aux ambitieux plans de l’Université McGill et de l’Hôpital général juif de permette l’éducation de la pathologie en ligne et de la rendre véritablement mondiale », a déclaré Pierre Le Fèvre, président et chef de la direction, Aurora Interactive.

Au sujet de l’Institut Lady Davis de recherches médicales de l’Hôpital général juif

Situé à Montréal au Québec, l’Institut Lady Davis de recherches médicales constitue l’organe de recherche de l’Hôpital général juif et entretient des liens étroits avec l’Université McGill. Avec plus de 150 chercheurs affiliés, l’Institut est un des plus importants centres de recherche biomédicale du Québec, voire du Canada. Ses chercheurs ont réalisé des percées majeures dans les domaines du VIH et du sida, du vieillissement, du cancer, des maladies vasculaires, de l’épidémiologie et de la psychosociologie. De ce fait, ils contribuent à la santé et au mieux-être de millions de patients montréalais, québécois et étrangers. (site web : www.ladydavis.ca)

À propos de l’Hôpital général juif

Oeuvrant pour une 75e année à prodiguer des soins « Au service de tous », l’Hôpital général juif a été un pilier du traitement médical de niveau supérieur pour des générations de patients de toutes origines, de Montréal et de partout au Québec, et même de l’extérieur. Un des hôpitaux les plus grands et les plus achalandés de la province offrant des soins de courte durée, et mettant à profit son expertise et son expérience, l’HGJ reste déterminé à améliorer le niveau de soins pour tous les Québécois en travaillant en collaboration étroite avec le gouvernement et son système de soins de santé. Pour souligner cette année d’anniversaire, l’Hôpital général juif réaffirme son engagement à veiller à ce que les patients reçoivent des soins de la plus haute qualité dans un environnement propre et sécuritaire. L’HGJ a été en mesure d’offrir ces services pionniers et novateurs en renforçant son rôle comme hôpital d’enseignement affilié à l’Université McGill, en agrandissant et en modernisant ses installations, et en réalisant des études de pointe à l’Institut Lady Davis pour la recherche médicale. Pour en savoir plus, veuillez consulter www.JGH.ca

À propos de l’Université McGill

McGill est l’un des établissements d’enseignement supérieurs les plus prestigieux du Canada et la principale université de recherche du pays. Notre effectif étudiant, issu de 160 pays, est le plus international des universités canadiennes offrant des programmes de médecine et de doctorat. L’Université McGill, le plus ancien établissement universitaire de Montréal, a été fondée en 1821 grâce à un legs d’un riche marchand, James McGill. À l’origine modeste collège, McGill est aujourd’hui une université trépidante comme en témoignent ses deux campus, ses 11 facultés, ses quelque 300 programmes d’études et ses 35 000 étudiants, donc 6 200 francophones et 6 800 étudiants étrangers. L’Université compte aussi quatre hôpitaux d’enseignement d’où sortent chaque année plus de 1 000 professionnels de la santé.

À propos d’Aurora Interactive

Aurora Interactive a développé mScope, une plateforme performante de logiciels basée sur le Web pour la simplification, la productivité et la facilité des communications. Le visualiseur Web universel mScope a des outils de collaboration pour visualiser des lames microscopiques et des images médicales à tout moment, n’importe où, indépendamment du format du fichier. Le logiciel comprend trois applications pour l’aide de vos besoins de communication basés sur votre toile de pathologie numérique, mScope pédagogique, mScope clinique et le visualiseur universel mScope. La mission d’Aurora est de faciliter une meilleure santé des patients et d’aider les membres de la communauté médicale à réaliser leur plein potentiel en éliminant les contraintes d’acquisition des connaissances, de diagnostic et de collaboration imposées par le temps et l’espace. www.aurorainteractive.com

WESTCHESTER, NY–(Marketwire – September 20, 2010) –

WHAT:
Mount Sinai and Westchester Health physicians to conduct a forum about the latest news in prevention and treatment of Breast Cancer and Diabetes. The panel will feature topics such as the new mammogram guidelines, prevention and treatment of breast cancer and fundamentals of diabetes detection and management.

This forum, designed to inform the community and create awareness about Diabetes and Breast Cancer, is FREE, but seating is limited.

RSVP is required. Call: 1 -800-MD-SINAI (800-637-4624) or E-mail: [email protected]

WHEN:
Wednesday, September 22, 2010, 6:00 PM to 8:30 PM

WHERE:
The Mount Kisco Holiday Inn, 1 Holiday Inn Drive, Mount Kisco, NY 10549

WHO:

• Moderated by Nancy R. Beran, MD, Medical Director of Westchester Health
• Diabetes Awareness – Tracy Breen, MD from Mount Sinai and Michael Goldberg, MD of Westchester Health
• Breast Cancer Awareness – Elisa Port, MD from Mount Sinai and Bonnie Litvack, MD, a community imaging specialist in Westchester

ABOUT THE MOUNT SINAI MEDICAL CENTER 
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of a few medical schools embedded in a hospital. It has more than 3,400 faculty members in 32 departments and 15 institutes. The school was awarded for Outstanding Community Service by the Association of American Medical Colleges Spencer Foreman in 2009.

The Mount Sinai Hospital, founded in 1852, is one of the nation’s largest and most-respected voluntary hospitals. In 2009 it was ranked among the nation’s top 20 hospitals. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.

ABOUT WESTCHESTER HEALTH ASSOCIATES
Westchester Health Associates physicians have been caring for patients in Northern Westchester for over thirty years. They have combined community practices to create a unique multi-specialty medical group, with over thirteen different specialties. Westchester Health has over 47 offices located throughout the area which provide personalized attention, as well as confidential and compassionate care. Integrated into each office is direct access to the area’s leading specialists and cutting-edge technology. Westchester Health Associates offers modalities such as electronic medical records, simplified communications between referring physicians, and direct communication with insurance companies.

Many of the Westchester Health physicians have been honored by their peers for their high standards of care, technical expertise, and compassion for their patients. Westchester patients are considered part of the Westchester Health family, which is 100,000 strong and growing.

ALEXANDRIA, VA–(Marketwire – September 20, 2010) –  As one of Hollywood’s self-proclaimed “fat funny guys,” Anthony Anderson has appeared in comedies including “Big Momma’s House” and “Kangaroo Jack,” but when he was diagnosed with type 2 diabetes at the age of 32, Anderson found that his weight was no laughing matter. In the October issue of Diabetes Forecast, the consumer magazine of the American Diabetes Association, Anderson opens up about incorporating diabetes management into his busy schedule and how his desire to go skydiving has inspired him to shed pounds. 

It was eight years ago that Anderson started experiencing symptoms of diabetes — he was tired and lethargic. “I chalked it up to being overworked,” he tells Diabetes Forecast. “I just thought I was running myself ragged.” When other symptoms started to appear, such as constant thirst and frequent urination, he saw his doctor and was diagnosed with type 2 diabetes. 

After his initial diagnosis, Anderson didn’t make many changes to his lifestyle, only to find that he wasn’t feeling better. The turning point was the idea of skydiving. “I want to skydive,” he says, “and one place I called told me you can’t weigh more than 235 pounds.” At 240 pounds, Anderson asked, jokingly, what he could do. Without missing a beat, the person from the skydiving center said, “Lose five pounds.” He started to run three miles a day, and cut back his portion sizes. “Now I’m well below 235, and I’m going to jump out of a plane!”

Diabetes was not new in Anderson’s family. His father had the disease, and his mother was recently diagnosed. Despite this, Anderson found that there were very few people talking about diabetes who spoke to him as a young African American man. He decided to be a spokesperson for Eli Lilly’s FACE Diabetes, an initiative to educate and empower African Americans about diabetes. “Statistics show that African Americans born today have a 50 percent chance of being diagnosed with type 2 diabetes,” Anderson says. “That’s what I’m doing now with the FACE Diabetes initiative through Lilly — getting as much information [as possible] and bringing awareness to our community and to our youth, because if we catch it early enough, this can be prevented.”

This issue of Diabetes Forecast also features an article titled “Why Me? Understanding the Causes of Diabetes.” It’s the question nearly everyone with a serious illness asks sooner or later: What did I do to deserve this? With both type 1 and type 2 diabetes on the rise, understanding the causes of diabetes may help curb the increase in new cases as well as quiet those pesky questions that have no easy answers.

The October issue offers more:

• Trick or Treat: Enjoying Halloween when you (or your kids) have diabetes
• Healthy Steps: School Walk for Diabetes promotes health and fitness in youngsters
• Research Profile: Can video games help people lose weight? Looking at how the “exergame” Dance Dance Revolution can be used in a diabetes management program

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MISSION, KS–(Marketwire – September 20, 2010) –  (Family Features) If you’re the parent of a teen or tween, chances are you’ve wondered, half-jokingly, if your child hears anything you say. The reality is that there are over 6.5 million American children ages 12 to 19 living with some form of hearing loss — and much of it is preventable.

Noise induced hearing loss
Every day, we experience sound in our environment — from television and radio, to household appliances and dreaded rush-hour traffic. Normally, we hear these sounds at safe levels that do not affect our hearing. However, when we are exposed to harmful noise, sounds that are too loud or loud sounds that last a long time, sensitive structures in our inner ear can be damaged, resulting in noise induced hearing loss (NIHL).

Noise induced hearing loss can be caused by a one-time exposure to an intense “impulse” sound, such as an explosion, or by continuous exposure to loud sounds over an extended period of time, such as a too-loud MP3 player. According to the National Institute of Health (NIH), long-term exposure to 80 to 85 decibels, or any more than 15 minutes exposure to 100 decibels, can lead to hearing loss. Music players like iPods can top 100 decibels when turned all the way up.

In fact, according to a survey conducted by Hear the World, a global initiative by leading hearing system manufacturer Phonak, exposure to high noise levels was found to not only result in gradual hearing loss, but also stress, aggression or insomnia in 73 percent of those surveyed.

MP3 players and your teen

A study released in the Journal of the American Medical Association found that 1 in 5 U.S. teens suffer from some form of hearing loss. Among other culprits named, from nutrition to environmental toxins, the use of the “earbud” style of headphones while listening to high decibel music was found to be one reason for the increase.

“It is no surprise that teens and young adults today are listening to music longer and potentially louder than years past,” said Dr. Craig Kasper, Chief Audiology Officer of Audio Help Hearing Centers and Hear the World spokesperson. “Ongoing exposure to loud sounds daily, through earphones for example, can have a direct impact on your hearing early in life and not just as you age.”

How loud is too loud? If an earbud headphone sounds loud to people nearby, it’s too loud.

If you suspect your child might have hearing loss, contact your local audiologist for a complete hearing screening. For more information on hearing loss and how loud is too loud, as well as an online hearing test, visit www.hear-the-world.com.

Reducing the risk
The good news is that noise induced hearing loss is 100 percent preventable.

“The impact of noise on hearing is often underestimated because the damage may take place gradually. As a result, many people do little to prevent the process of hearing loss that takes place throughout their lives due to the noise pollution around them,” said Dr. Kasper.

To protect hearing, Dr. Kasper recommends these tips for teens and tweens:

1. Be mindful of your hearing. Think about the level of noise you’re exposed to as well as the duration of time you’re in that noise.
2. When attending concerts or loud events, wear hearing protection. Most of us would never think to sunbathe without some form of SPF protection. Using either over-the-counter earplugs or custom-molded hearing protection is like SPF for your ears.
3. When listening to your iPod or other MP3 player, invest in a sound-isolating earphone, such as the Audéo PFE by Phonak (see sidebar). This will reduce the amount of environmental sounds and allow you to turn the volume down.

Sound waves travel through the ear canal to the inner ear, where tiny hair cells convert the sound into nerve impulses that travel to hearing centers in the brain. Excessive noise can damage those cells and cause permanent hearing loss.

Top five misconceptions about hearing loss
1. Hearing loss is only for the elderly: Only 35 percent of people with hearing loss are older than age 64. There are over 6.5 million American children ages 12 to 19 living with some form of hearing loss.
2. If my child or I had hearing loss, my family doctor would have told me: Only 14 percent of physicians routinely screen for hearing loss during a physical.
3. Your hearing loss cannot be helped: With modern advances in technology, nearly 95 percent of people with a sensorineural hearing loss — a type of hearing loss in which the root cause lies in the inner ear — can be helped with hearing aids.
4. Hearing aids are large, clunky and obvious: Many modern hearing aids are nearly invisible to the naked eye and smaller than a quarter.
5. Hearing loss isn’t serious enough to treat: Hearing loss can create social and emotional barriers for the individuals living with it, or the families of those it affects. Research shows that when left untreated, hearing loss can lead to reduced earning power, disruptions in family life and can cause a wide range of other psychological problems.

Signs of hearing loss in your teen

• Loss of hearing sensitivity, first to high-pitched (high-frequency) sounds, then eventually to lower pitches.
• Difficulty hearing conversations, especially in a group setting or in a noisy environment.
• Temporary or permanent ringing, buzzing or fluttering in one or both ears.
• Often asks people to repeat themselves.
• Needs to set the TV or radio volume louder than other people.
• A sense of fullness in the ears.
• Voices and other noises sound muffled and/or distorted.

Audéo PFE Perfect Bass
The Audéo PFE (Perfect Fit Earphones) Perfect Bass are a set of high-end, sound-isolating earphones by leading hearing systems manufacturer Phonak. The Audéo PFE provides exceptional fit with different, replaceable ear tips, great sound (even at low volume levels) without sacrificing the health of your ears, and starts below $100. The Audéo PFE Perfect Bass can be purchased online at www.audeoworld.com.

SAN FRANCISCO, CA–(Marketwire – September 16, 2010) – Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today it has filed a US Provisional patent application covering the use of AsepticSure™ for disinfecting sports equipment and training facilities.

Dr. Michael Shannon, Medizone’s Director of Medical Affairs, commented, “The CDC estimates that 100,000 people a year die from MRSA (staph infections). The CDC estimates 20% of hospital acquired MRSA infections cause death. Unfortunately, a new variant of MRSA is emerging within the broader community which has a much higher fatality rate, by some estimates reaching 50%. This newer variant is now being discovered in sports training facilities including those associated with professional, college and high school level teams. Recent investigations have revealed a broad range of bacteria at high concentration actually residing within unclean sports equipment which tend to be covered in mucus, sweat, dead skin and occasionally blood; ideal culture media for bacteria, fungi and mold. There have been a number of recent cases in which the use of contaminated sports equipment has lead to infections so severe that players, children in particular, have become critically ill from the resulting sepsis. So we believe that there is an obvious public health need to be addressed with AsepticSure™. Our technology is safe and we now have hard data to substantiate our claim of high efficacy in dealing with this growing community problem.”

Medizone’s CEO, Edwin Marshall, stated, “Our researchers have identified nuances in addressing the disinfection of sports equipment that again allows us to increase the patent protection wall being built around our AsepticSure™ sterilization system. We believe all of our recently filed additional patent applications, both US applications and international applications, will prove to greatly enhance the commercial value of our technology.”

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Click here to see all recent news from this company

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – September 15, 2010) – Partners to exploit new approach
to the delivery of nitric oxide

www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced that it has agreed
with its partner Merck, known as MSD outside the United States and Canada,
to expand the scope of their worldwide license agreement, originally
executed in 2006. This decision follows the discovery of a new approach to
nitric oxide (NO) donation during the course of the joint research program.

This approach may be used to develop new classes of NO-donating new
molecular entities (NMEs), designed to offer a different mechanism for
controlling the delivery of NO while retaining the potential therapeutic
benefits. Additional information will not be disclosed for reasons of
commercial confidentiality.

The clinical program evaluating several NO-donating antihypertensive
candidates from the original agreement in healthy volunteers and mild to
moderate hypertensive patients has now been completed and none of the
compounds tested will be further advanced in development.

NicOx has developed a world-leading position in the therapeutic application
of NO-donating compounds. NO is an endogenous cell-signaling molecule of
basic importance in physiology and there is significant evidence that
certain diseases are related to a deficiency in the production of nitric
oxide. This new approach with Merck continues to build on the concept of a
slow release of NO with a sustained pharmacological effect at tissue level.

Under the revised agreement, Merck has the right to develop NMEs using this
new approach in certain cardiovascular indications. NicOx will have the
right to develop product candidates in other indications. NicOx and Merck
will pay development milestones and royalties to the other partner on
products emerging from their respective research programs. NicOx and Merck
have agreed that no further announcements on the compounds developed by
Merck under the collaboration are anticipated unless and until a drug-
candidate advances into phase 2 clinical studies.

Ennio Ongini, Vice President Research at NicOx, commented: “The research
collaboration with Merck has been very fruitful, and it is as a result of
the excellent scientific interaction that this new approach to NO donation
was discovered. Novel molecules using this approach offer an exciting new
alternative route to exploit the biological properties of NO which can
potentially be used in a wide range of therapeutic areas.”

Under the revised agreement, each company will be responsible for funding
their own research and development costs. NicOx and Merck do not have the
option to co-promote any NMEs from the other partner resulting from this
expanded license.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the FDA provided a Complete
Response Letter to the New Drug Application (NDA) for naproxcinod stating
that it does not approve the naproxcinod application. The naproxcinod
Marketing Authorization Application (MAA) submitted by NicOx in December
2009 is currently under review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of select
cardiovascular indications, eye diseases and dermatological diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of NicOx S.A. to
differ from those contained in the forward-looking statements, please refer
to the Risk Factors (“Facteurs de Risque”) section of the Document de
Reference filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

CONTACTS

www.nicox.com

NicOx

Gavin Spencer – Vice President Business Development Tel +33 (0)4 97 24 53
00 – [email protected]

Media Relations

Financial Dynamics

Europe

Guillaume Granier (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Stéphanie Bia (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Jonathan Birt (UK) – Tel +44 (0)20 7269 7205 – [email protected]

United States

Robert Stanislaro – Tel +1 212 850 5657 – [email protected]

Irma Gomez-Dib – Tel +1 212 850 5761 – [email protected]

NicOx S.A.,

Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313,
06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 – Fax +33
(0)4 97 24 53 99

This information is provided by HUGIN

NEEDHAM, MA–(Marketwire – September 14, 2010) –  The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private foundation funding collaborative translational science programs, announced today an important new publication in the September 8, 2010 online issue of the journal Science Express. The paper, co-authored by AMRF-funded scientists Victor Velculescu of Johns Hopkins University and Dennis Slamon of the University of California, Los Angeles, identifies two genes not previously implicated in ovarian clear cell carcinoma (OCCC). This finding provides two novel targets for the development of new drugs to treat this aggressive form of ovarian cancer that is generally resistant to current therapies.

“The collaboration among Drs. Velculescu, Slamon and their other Adelson Medical Research Foundation-funded colleagues brings together distinguished laboratories with capabilities in cancer genomics, genetics, and the treatment of cancer in women to uniquely analyze ovarian tumors,” said Dr. Miriam Adelson, Trustee and Executive Director of the Foundation. “This is an example of our Foundation’s unique collaborative model in action,” noted Sheldon G. Adelson, Trustee of the Foundation and Chairman of the Board and Chief Executive Officer of Las Vegas Sands Corp. “By funding collaborative teams from a number of major biomedical research institutions and a variety of scientific disciplines, we are bringing new insights to some of the most challenging areas of cancer research,” Dr. Adelson elaborated.

“This study implicates PPP2R1A as a novel oncogene and ARID1A as a novel tumor suppressor gene in OCCC, neither of which had previously been implicated in ovarian cancer,” noted Dr. Kenneth H. Fasman, Vice President and Chief Scientific Officer of AMRF. “This opens the door for two new directions in cancer drug discovery,” Fasman said.

Victor E. Velculescu, M.D., Ph.D., is Associate Professor of Oncology and Director of Cancer Genetics at the Ludwig Center for Cancer Genetics and Therapeutics of the Johns Hopkins Kimmel Cancer Center. He has co-authored many seminal papers on cancer genomics with his Hopkins co-authors Bert Vogelstein and Kenneth W. Kinzler. Dennis J. Slamon, M.D., Ph.D., is director of Clinical/Translational Research, and director of the Revlon/UCLA Women’s Cancer Research Program at the Jonsson Comprehensive Cancer Center. He is Professor of Medicine, chief of the Division of Hematology/Oncology and Executive Vice Chair for Research for UCLA’s Department of Medicine. For 12 years, Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. Drs. Velculescu and Slamon are members of the Adelson Medical Research Foundation’s ovarian cancer research collaboration.

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, established in 2006, is a private foundation committed to a model of open and highly integrated collaboration among outstanding investigators who participate in goal-directed basic and clinical research to prevent, reduce or eliminate disabling and life-threatening illness. The Foundation creates a culture of scientific discovery, evaluation, and clinical application directed by the experiences of scientists who are not bound by searching for the cure of any single disease. Programs within the Foundation are defined in broad terms. The Adelson Program in Cancer Research pursues therapies targeted to the mechanisms that make cells malignant, and the Adelson Program in Neural Repair and Rehabilitation seeks to manipulate the regeneration of axons in the brain, spinal cord and peripheral nerves.

For additional information on the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, please visit www.adelsonfoundation.org/AMRF.

ALEXANDRIA, VA–(Marketwire – September 14, 2010) –  Good food, good music, and good conversation — three key ingredients to many Hispanic/Latino family gatherings. But what is missing from many of those get-togethers is a life-saving conversation about the family’s medical history. This Hispanic Heritage Month (September 15-October 15), the American Diabetes Association is encouraging people to discuss any family history of diabetes, a conversation that could help stop diabetes before it starts.

Type 2 diabetes disproportionately affects Hispanics/Latinos. In fact, the rates of type 2 diabetes are almost double that of non-Hispanic whites. More than 10% of Hispanics/Latinos in the United States have been diagnosed with diabetes.

“It is particularly important for Hispanics/Latinos to know they are at higher risk for type 2 diabetes,” said Lorena Drago, RD, CDE, American Diabetes Association volunteer. “It is common for families to have multiple members with diabetes, but they never talk about it. These family discussions are necessary so everyone knows their risk, especially the younger generations.”

If current trends continue, 1 in 2 minorities born today will develop diabetes. Oftentimes type 2 diabetes is not diagnosed until one or more of its complications have begun to develop, including blindness, nerve damage or heart disease. Hispanics/Latinos are at higher risk for developing these complications.

The good news is type 2 diabetes can be prevented or delayed with healthy eating and exercising. “By exercising 150 minutes a week, such as 30 minutes 5 days a week, and losing 5 %-10% of your body weight, you could reduce your chances of developing type 2 diabetes by 58%,” said Drago. “By making changes gradually, instead of all at once, you can stop type 2 diabetes from developing or stop diabetes complications from occurring.”

The American Diabetes Association offers various family-friendly resources to help people successfully make lifestyle changes to reduce the risk of developing type 2 diabetes or diabetes complications.

• MyFoodAdvisor™ — Available in English and Spanish at www.diabetes.org/myfoodadvisor, this award-winning online tool provides nutrition information for people with diabetes, those at risk, and anyone who wants to lose weight. Users can track what they eat, find healthier alternatives and search recipes. The comprehensive database includes many culturally appropriate foods for Hispanics/Latinos.

  “MyFoodAdvisor can help you explore different types of foods. For example, eating one extra serving of fruits or vegetables a day is a small change you can make to get you and your family started towards a healthier meal plan,” commented Drago.

• Feria de Salud Por Tu Familia — Feria is the Association’s outdoor community event which captures the festive elements of a street fair but maintains the important aspects of choosing and managing a healthier lifestyle for the entire Hispanic/Latino family. This family event includes music, dancing, nutritional information, cooking demonstrations and a variety of product and service booths. Visit www.diabetes.org/feria for event listings in your area.

  “Feria can arm you with information to help stop diabetes and its complications in its tracks. The event provides you and your family with creative ways to become active, new ideas for healthy recipes, and greater awareness of what resources are available in the community,” said Drago.

• Stop Diabetes® — People from around the country are joining the Association’s movement to Stop Diabetes once and for all. By visiting www.stopdiabetes.com, calling 800-DIABETES, or texting* JOIN to 69866, you can find out how to become involved in the movement. There are opportunities for every member of the family to share, act, learn and give and help stop diabetes.

  “Whether you want to join the Stop Diabetes movement for yourself or a loved one, it is important that we stand up together against this disease and say the status quo is no longer acceptable. Too many people and their loved ones have suffered from diabetes’ terrible toll. Joining the movement is the first step to say enough is enough,” commented Drago.

  *Standard data and message rates apply.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

TORONTO, ONTARIO–(Marketwire – Sept. 14, 2010) –

Attention Health and Medical Editors

On September 23, 2010, media are invited to an in-depth briefing with senior scientists on current stem cell research activity. Toronto’s McEwen Centre is one of the top regenerative medicine research facilities in the world and a leader internationally in the generation of reproducible heart cells. Research at the McEwen Centre also holds important implications for diabetes, lung disease and diseases of the blood as well as neurodegenerative disease.

Join us to learn more about the most recent developments in stem cell research at the McEwen Centre.

RALEIGH, NC–(Marketwire – September 14, 2010) –  INC Research ®, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, has appointed three new medical directors to oversee the medical management teams in each region and enhance its high standard of scientific and medical support to global clinical trials. Dr. Claudia Trillo joins as medical director in Buenos Aires, Argentina, Dr. Rick Chen joins as associate medical director in Beijing, China, and Dr. Bhawana Awasthy joins as Senior Medical Director located in Gurgaon, Delhi, India.

“We are thrilled to expand our global Medical Management team with these esteemed physicians,” said Malcolm Fletcher, chief medical officer of INC Research. “By hiring very seasoned medical professionals who combine patient-care experience with trial-management expertise, our team is very good at understanding the investigator site environment. By immersing themselves into the safety and efficacy of a trial, they are able to make critical steering decisions that have a profound effect on the reliability of the results.”

Dr. Trillo in Buenos Aires has 14 years of industry experience in multiple indications. She started her industry career at Quintiles, followed by roles at Searle, GSK and Kendle. She trained in medicine at the Universidad de Buenos Aires, Medical School, and has board certification in Critical Care Medicine.

Dr. Chen in Beijing has more than 10 years of academic experience in ischemic stroke, cardiovascular disease and rheumatoid arthritis research. He is experienced in selecting and initiating investigate sites, providing training and performing routine site monitoring during the process of clinical trials, He has also contributed to furthering research education by publishing more than 10 papers in peer-reviewed journals.

Dr. Awasthy in Gurgaon brings 17 years of combined clinical-practice and clinical-research experience to INC Research. She is a proven leader both in Industry and among her medical colleagues, maintaining her specialization in oncology while designing, writing and implementing studies in Phase I through Phase IV on a global level.

INC Research’s Medical Management team is comprised of in-house physicians who provide round-the-clock medical monitoring services, as well as scientific and medical support for project management teams and investigative sites. The team has a diversity of backgrounds and specialties and covers the range from small proof-of-concept studies to large multinational pivotal studies with equal flexibility. To learn more about INC Research’s Medical Monitoring trial services, click here.

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization (CRO) with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

Click here to see all recent news from this company

JERICHO, NY–(Marketwire – September 13, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that it believes that the future looks very bright for itself and its sublicense partner, Montreal-based Genesis Biopharma, Inc., as they continue making progress regarding their new compound in development for the treatment and potential cure of Painful Diabetic Neuropathy (PDN).

According to the International Diabetes Federation the global health expenditure on diabetes is expected to total at least USD 376 billion in 2010 and USD 490 billion in 2030. (http://www.idf.org/webdata/docs/PIIS0168822710000495.pdf)

Back in 2003 the American Diabetes Association estimated that in the U.S. the total annual cost of treating diabetic peripheral neuropathy and its complications was $10.91 billion. (http://care.diabetesjournals.org/content/26/6/1790.full)

ABOUT PDN:

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

1. According to the World Health Organization there are approximately 220 million people worldwide who have diabetes

   (http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S., according to the 2007 National Diabetes Fact Sheet, a total of 23.6 million had diabetes of which 17.9 million were already diagnosed and the rest, 24%, were undiagnosed.

   (http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you add the undiagnosed cases to the 220 million reported by the World Health Organization the total number could exceed 270 million worldwide.

2. Diabetic neuropathy can cause nerve damage in the feet that leads to decrease or loss of sensation. As a result, a blister or a cut can go unnoticed. Any infection that might ensue can result in tissue death (gangrene) and in some cases severe damage can lead to amputation of toe, foot or even leg. Each year about 80,000 – 84,000 amputations are performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
   http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).

   How many of these amputations could have been avoided had a solution been made available?

Mr. Leo Stella, CEO of Genesis, has stated: “Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs cannot cure the cause. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition.”

Dr. Jan Stahl, CEO of TRDX, commented: “The opportunity is very significant for all the stakeholders in this PDN solution. We will continue our efforts to make this potential cure a reality and deliver quality value for our shareholders.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

KYLE, TX–(Marketwire – September 9, 2010) –  CommuniCare Health Centers, a Federally Qualified Health Center that provides health care in Bexar and Hays Counties, announced today that it has received a $56,533 grant from the Austin Affiliate of Susan G. Komen for the Cure®. The grant will provide low-income, uninsured women in Hays County with greatly needed educational information about breast cancer, access to clinical breast exams, and mammograms.

“We are so pleased to receive the grant from the Austin Affiliate of Susan G. Komen for the Cure® and look forward to making breast health services available to more women in Hays County,” said Debbora A. Thompson, Chief Executive Officer of CommuniCare Health Centers. “Without organizations like the Komen Foundation many low-income, minority, uninsured women would not have access to critical breast health screenings.”

The services provided by the grant will be offered to uninsured women aged 40 to 64 at CommuniCare’s health center at 1340 Wonder World Drive in San Marcos and at its new health center in Kyle, CommuniCare Health Centers – Kyle at 2810 Dacy Lane. To access services funded by this grant, please call 512.392.1718. CommuniCare will be opening CCHC-Kyle, on September 20, 2010 where medical, dental and behavioral health care will be available to area residents. 

About the Austin Affiliate of Susan G. Komen for the Cure:
The Austin Affiliate of Susan G. Komen for the Cure® has been working to better the lives of those facing breast cancer in the Greater Austin community since 1999. Through events such as the Komen Austin Race for the Cure® and other philanthropic endeavors, the Austin Affiliate has invested nearly $7 Million in community breast health programs in Bastrop, Caldwell, Hays, Travis, and Williamson Counties. The Affiliate makes grants to local hospitals and community organizations that provide breast health education and breast cancer screening and treatment programs for medically underserved women.
For more information on the Austin Affiliate of Susan G. Komen for the Cure® please visit www.komenaustin.org.

About CommuniCare:
CommuniCare Health Centers (CCHC) has served San Antonio for over 38 years. CCHC provides medical, dental and behavioral health services to uninsured and underserved residents in Bexar and Hays counties and delivered more than 151,000 visits in 2009 in two health centers in San Antonio and one in San Marcos. As a non-profit community health center, it serves those with Medicaid, Medicare, medical insurance and those that do not have insurance, charging on a sliding-fee scale based on annual household income and family size. For more information on Barrio Comprehensive Family Health Care Center, Inc. dba CommuniCare Health Centers please visit www.communicaretx.org.

DENVER, CO–(Marketwire – September 9, 2010) –  The Breakaway Group will host an exclusive group of healthcare leaders, educators and innovators at the Inverness Hotel & Conference Center in Denver, from September 23-25, for the 2010 Healthcare Forum: Beyond Implementation, The New Leadership Agenda for Lasting EMR Adoption. Featuring a presentation by Wil Yu, Special Assistant, Innovations and Research, Strategic Health IT Advanced Research Projects, Office of the National Coordinator for Health IT, the central theme of the forum centers on the changing leadership agenda for three roles in healthcare: the CEO, CIO and Clinical Leadership.

Attendees and presenters include top leaders from Trinity Health, UT Medical Group, Arkansas Children’s Hospital, Baptist Health System and Hartford Health Care, and others. The 2010 Healthcare Forum continues the conversation launched in 2007 at the Healthcare Summit in Vail, Colo., where discussion focused on the challenge of how to treat an HIT implementation as more than a single event. 

“The Healthcare Forum provides a way for C-level executives to collaborate on finding successful ways to shift leadership priorities, to refocus organization efforts around EMR adoption,” said Charles Fred, chief executive officer of The Breakaway Group. “We are excited to offer the results of our research as a way to facilitate meaningful use and sustainable EMR adoption in the healthcare industry.” 

Recent Research Serves as Foundation for New Leadership Agenda
In the face of increased pressure to adopt new technology, healthcare executives have been led to reprioritize their everyday roles. Recent in-depth research from The Breakaway Group into the major barriers of EMR adoption and improved clinical outcomes (Beyond Implementation: A Prescription for Lasting EMR Adoption, 2010, Haugen, H., Woodside, J.) will serve as a foundation for the leadership agenda discussion. 

The authors, Dr. Heather Haugen and Dr. Jeffrey Woodside, M.D., conducted more than 18 months of research with leaders and healthcare organizations representing more than 3,200 physicians and 350 ambulatory sites. Through case studies and research, they examine why the transition to EMR is often overly costly, lengthy and frustrating.

“Despite the significant benefits of electronic medical records, healthcare organizations are not seeing the financial and clinical outcomes they had hoped for,” said Dr. Haugen, co-author of Beyond Implementation. “After investigating the outcomes of poor adoption and why physicians don’t get the full potential from EMR, we have identified one common thread. Too often, the primary focus is on go-live implementation when instead, this step should be the beginning of a sustained effort for the life of the application.”

About The Breakaway Group
The Breakaway Group helps healthcare providers quickly adopt new technology through a research-based method that uses innovative simulations and coaching to help improve patient care and safety. The firm’s unique approach to learning is based on the best-selling book “Breakaway” by CEO and Founder Charles Fred. For more information, visit www.thebreakawaygroup.com.

SCOTTSDALE, AZ–(Marketwire – September 9, 2010) – Top 10 women’s health site EmpowHER today launched what is expected to be the largest online movement for women’s health in the next year — the 1000Women campaign.

Expecting to engage 1,000 women who will each recruit another 1,000 women to participate in this classic pay-it-forward viral effort; the campaign’s goal is to get 1 million women to share their inspirational health stories with friends, family, and women they’ve never even met. Campaign participants can do this by creating profiles on 1000Women.com where they can: “tell a friend” about the campaign; share their own personal health and wellness story — including pictures and videos if they wish, or simply vote for another woman’s story that inspires them.

When 1 million women have engaged in the campaign, EmpowHER will donate $50,000 toward women’s health research.

“Participants in this campaign are not required to spend a penny. Every time a new woman signs up to share a story, vote for a story, or share the campaign with others, money will be donated by EmpowHER to fund women’s health research,” said Thom Brodeur, Chief Marketing Officer for EmpowHER and campaign architect. “Our challenge to women is simple. Open your hearts, log onto the website, and pass it along. We’ll open our wallet and do the rest. We’re partnering with women to improve their health and change their lives, and we’re honored to play a role.”

The majority of campaign funds will be donated to HealthyWomen, the nation’s leading nonprofit health information source for women. For more than 20 years, HealthyWomen has been committed to improving women’s health through public education campaigns grounded in research among women nationwide.

“Studies show that when women share their health issues with other women, their state of mind improves, sometimes even having positive effects on their overall health,” said Jay K. Harness, MD, a member of EmpowHER’s Medical Advisory Board, President of Breast Surgery International and breast surgeon in Orange County, Calif. “For example, a recent report from the California HealthCare Foundation reported that when patients managing the same chronic condition share observations with each other, their collective wisdom can yield clinical insights well beyond the understanding of any single patient or physician.”

Dr. Harness, past president of the American Society of Breast Surgeons, goes on to say, “Studies have found that cancer patients who were isolated and lacked social interaction had greater tumor growth and worse prognosis. We firmly believe that loneliness and isolation can have a significant impact on a patient’s long-term battle with a disease.” Dr. Harness concluded that online communities are a great resource for patients to share and connect, but are not a substitution for oversight and guidance from a patient’s medical team.

“Women need to advocate for themselves and each other by calling for more gender-specific health research,” said Michelle King Robson, Founder, Chairperson and CEO of EmpowHER. “Much of the world’s health-related research remains male dominated, signaling there is still much to learn about women’s unique health conditions and the specific effects of procedures, drugs and diagnostics on women. This campaign was created to give women a voice in their own health, and to provide financial support to organizations dedicated to advancing women’s health research and advocacy.”

King Robson has witnessed this trend first-hand. Her site, launched just 24 months ago, reaches nearly 1.2 million unique visitors and viewers every month from women sharing their most intimate health conditions and then connecting with others for support. “I started this site after I experienced my own health nightmare and began telling my story. What has occurred has been a firestorm of other women who have found solace and better health by sharing on EmpowHER.com. We now want to take this to a new level of connectivity for all women around the globe by giving them a voice in their health through this campaign.”

To participate in the 1000Women Campaign, please visit www.1000Women.com.

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.EmpowHER.com.

About HealthyWomen
HealthyWomen (HW) is the nation’s leading independent health information source for women. For more than 20 years, women have been coming to the HW for answers to their most pressing and personal health care questions. HW provides health information through a wide array of online content and print publications that are original, objective and reviewed and approved by medical experts. Its website, www.HealthyWomen.org®, was recognized by ForbesWoman as one of the “Top 100 Websites for Women” and was named the top women’s health website by Dr. Mehmet Oz in O, The Oprah Magazine and by Good Housekeeping magazine. To learn more, visit www.HealthyWomen.org.

id=”nav_links”>

ROCHESTER, NY–(Marketwire – September 8, 2010) –  The Pediatric Cataract Initiative (www.PediatricCataract.org) is now accepting applicants for its inaugural single small research grant. US$75,000 will be awarded to a qualified individual, institution or organization investigating the causes of pediatric cataract and/or improved treatment tools and protocols. The submission deadline is November 15, 2010.

The grant is intended to support innovative research that can be carried out in 12 months with limited resources. Applicants may submit more than one proposal provided that each is scientifically distinct. Please visit www.pediatriccataract.org/grant_funding.html to download the complete request for proposals.

The newly founded Pediatric Cataract Initiative is a partnership between the Bausch + Lomb Early Vision Institute and Lions Clubs International Foundation to identify, fund and promote innovative methods of overcoming pediatric cataract — a debilitating childhood condition that clouds the eye’s natural lens — for the long-term benefit of children, their families and their communities.

In addition to its global research grant, the Initiative is committing funding and support during its first year to innovative, scalable prevention and treatment programs in the People’s Republic of China, where at least 40,000 children are estimated to suffer from pediatric cataract. The prevalence of pediatric cataract ranges from one to four children per 10,000 births in developing countries — ten times the rate of occurrence in developed nations.

For additional information, visit www.PediatricCataract.org or follow the Initiative at www.twitter.com/PCInitiative and www.Facebook.com/PediatricCataract.

About the Bausch + Lomb Early Vision Institute
The Bausch + Lomb Early Vision Institute is a program of the global eye health company focusing on children’s vision research, treatment, prevention and advocacy. Founded in 1853, Bausch + Lomb is one of the best-known and most respected healthcare brands in the world, with its contact lenses and solutions, ophthalmic pharmaceuticals, and ophthalmic surgical products available in approximately 100 countries. For more information, visit www.bausch.com/.

About Lions Clubs International Foundation
Lions Clubs International Foundation is the grant-making body of Lions Clubs International, the world’s largest volunteer service organization. The LCIF SightFirst program, Lions’ flagship initiative, builds comprehensive eye care systems to fight the major causes of blindness and care for blind and visually impaired persons. Since 1990, the SightFirst program has helped restore sight to more than 30 million people around the world, having invested more than US$237 million in surgeries, the improvement of hundreds of eye care facilities and training of thousands of eye care professionals. For more information, visit www.lcif.org.

Click here to see all recent news from this company

MADISON, WS–(Marketwire – September 8, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that 82 studies examining the use of the TomoTherapy^® treatment system to treat common, complex and rare tumors throughout the body will be showcased at ESTRO 29, September 12-16, 2010, in Barcelona. The studies examine use of the TomoTherapy system on head and neck, prostate, breast and lung tumors, as well as for treating blood cancers, mesothelioma and pediatric patients.

In one of the most promising papers, researchers from San Raffaele Scientific Institute in Milan, Italy compared TomoTherapy to other radiation therapy solutions using Pareto front analysis to explore the ability of these treatment methods to improve target coverage without sacrificing organs at risk (OAR) or other constraints. Researchers reported that “for all simulations RapidArc^® met less of the optimization criteria, while TomoTherapy was able to produce the most homogeneous dose and have the capability to conform dose distributions better than RapidArc^®.”

Head and Neck Cancers
Among the numerous studies on head and neck tumors, two studies compare arc therapy to helical TomoTherapy radiation delivery. Exploring the treatment of patients with oropharyngeal cancer, researchers in Belgium and the Netherlands concluded that in the treatment of head and neck cancer, helical TomoTherapy treatment times are less than both Smart Arc and step and shoot techniques. In fact, TomoTherapy treatment was fastest of all techniques examined, at 6.6 minutes, compared to 7.5 minutes for Smart Arc and longer times for other intensity-modulated radiation therapy (IMRT) techniques, while delivering the best homogeneity and equivalent or better OAR sparing.

Similarly researchers in Austria and Germany compared four different technologies for a parotid gland sparing head and neck treatment technique with simultaneous integrated boost (SIB). Their research showed that the TomoTherapy platform delivered the lowest doses to the parotids and spinal cord and achieved the shortest treatment time — eight minutes versus nine to 24 minutes for the other solutions examined.

Prostate Cancer
Eight studies focused on the use of TomoTherapy technology to treat prostate cancer in more than 280 patients. The studies showed excellent outcome for these patient groups, extending up to more than four years post-treatment. TomoTherapy? treatments resulted in very low toxicities and side effects, even with delivery of escalated doses.

Breast Cancer
In a study of 30 stage III breast cancer patients, researchers at The Ottawa Hospital Regional Cancer Centre in Canada examined early results of loco regional breast radiation using IMRT delivery by the TomoTherapy system. The treatment area included the breast and chest wall, as well as supraclavicular, axillary and internal mammary nodal regions. The TomoTherapy system enabled conformal treatment that limited dosage to healthy surrounding tissue, including the heart, lungs, esophagus and thyroid. Researchers concluded that IMRT with the TomoTherapy system “for loco regional breast radiation is feasible and well tolerated with minimal acute and moderate-late skin effects.”

Lung Cancer
Research done at San Raffaele Scientific Institute was designed to assess the feasibility of the TomoTherapy platform to deliver hypofractionated treatments in 15 patients with inoperable locally advanced non-small cell lung cancer (NSCLC). After re-evaluating 12 patients in the study five months post-treatment, 42 percent of the patients had a complete metabolic response and 33 percent a partial response. The study also showed that these patients experienced less toxicity and were able to complete treatment in 13 treatment sessions rather than 20, as is the norm. The study concluded that hypofractionation in radical treatments for locally advanced NSCLC by means of helical TomoTherapy delivery is feasible and shortens the overall treatment time, and that the treatment allows an excellent toxicity profile.

Complex Cases
Highlighting the effectiveness of TomoTherapy radiation therapy in complex cases, a study of TomoTherapy use for one-and-a-half years at Greater Poland Cancer Centre in Poznan, Poland noted, “TomoTherapy is a method by which we can often achieve the treatment impossible to obtain on the conventional linacs or the treatment with a significantly better dose distribution than for conventional linacs.”

The ability of TomoTherapy technology to treat complex cases was also outlined in a number of studies, including:

• Mesothelioma — This is a disease that is difficult to treat because of the size and complex shape of the tumor, which involves the outer lining of the lungs and internal chest wall. In a study at San Raffaele Scientific Institute, researchers compared two groups of patients treated with the TomoTherapy platform, with one receiving a simultaneous integrated boost (SIB). Those patients receiving the SIB experienced significant benefits, with a one-year survival rate increasing to 72 percent, compared to 43 percent for the other group. Additionally, patients receiving a SIB did not experience a relapse for an average of 16 months versus six months for the non-SIB group.

• Reirradiation of head and neck tumors — Researchers in Korea investigated the efficacy and toxicity of using the TomoTherapy system to reirradiate head and neck tumors in patients who were inoperable. Nine patients were treated in this study, with median follow up of nine months. Study results showed that there was a treatment response rate of 66.7 percent. Additionally, patients experienced extremely low acute toxicities with only grade 2 skin reactions noted, and no sign of late toxicity.

• Total Marrow Irradiation (TMI) — Researchers at City of Hope in Los Angeles conducted a dosimetric analysis of 51 patients treated with TMI or total marrow and lymphatic irradiation (TMLI). The results showed that no patient experienced greater than grade 2 toxicity, with half the patients experiencing no nausea, which is a common side effect in other similar treatments. Additionally, researchers noted that dosimetric analysis demonstrated that TMI and TMLI with TomoTherapy technology may have potential advantages over other forms of targeted systemic radiation therapy.

• Pediatric — Four studies focused on treatment of pediatric patients, with three of those looking at treatments for medulloblastoma. The fourth study recounted the experiences of 62 patients, ranging in age from one to 14, at Grupo Instituto Madrileño de Oncologia (IMO) in Spain, which examined how the TomoTherapy system could be used in young patients to deliver high doses of radiation while preserving healthy organs. The study showed that the TomoTherapy approach allowed manageable levels of toxicity, and was effective in treating the majority of the patients — upon post-treatment evaluation, 58 percent did not have any evidence of illness, 7 percent showed a partial response and another 14 percent remained stable.

To learn more about the TomoTherapy treatment system, visit TomoTherapy at ESTRO 29 in booth 60, September 12-16 in Barcelona.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

RapidArc^® is a trademark of Varian Medical Systems.

SILVER SPRING, MD–(Marketwire – September 2, 2010) –  A new laboratory, designed and built in accordance with international guidelines, opened September 1 in Maseru, Lesotho. The Makoanyane Military Hospital Laboratory now offers an expanded testing menu, including CD4 and Acid Fast Bacilli microscopy, and separate rooms dedicated to specimen reception, microbiology, chemistry, hematology and CD4 testing. The formerly limited, one-room hospital lab was transformed through a collaborative effort of The US Department of Defense and CDC’s Global AIDS Program to support the Lesotho Defense Force’s facility.

The Association of Public Health Laboratories (APHL) provided on-site support and technical assistance to the Lesotho Defense Force, the agency that operates the military hospital, through its cooperative agreement with CDC/GAP in support of PEPFAR.

Senior APHL consultant Kim Lewis worked on-site in Maseru on laboratory design, procurement of equipment and supplies, renovation oversight, organizing laboratory workflow and operations, staff development and initial steps toward WHO Accreditation through implementation of the Strengthening Laboratory Management Towards Accreditation Program. 

APHL will continue to support the new facility by implementing a quality system to assure accurate, reliable and timely test results.

“The laboratory provides access to testing services for a population with high rates of TB and HIV, and enables medical providers to effectively treat these diseases,” said Lewis. “The success of this collaboration is measured in the improved health of the people of Lesotho. The new lab will hopefully affect the well-being of families and lead to a better future for their children. We expect it to serve as a model for other countries.”

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

CASCO, ME–(Marketwire – September 2, 2010) –  Camp Sunshine, a one-of-a-kind national retreat in Casco for children with life-threatening illnesses and their families, today announced that Hyundai Hope on Wheels has selected the organization to receive a $100,000 “Hope Grant.” Hope on Wheels is a partnership of 800 Hyundai dealers across the United States and Hyundai Motor America aimed at raising awareness of childhood cancer. Camp Sunshine will use funds from the grant to sponsor two additional oncology sessions at the Camp in 2011.

On Sept. 25 — during National Childhood Cancer Awareness Month — Hope on Wheels will visit Camp Sunshine’s Casco campus and participate in a check presentation ceremony to commemorate the event. Throughout the month, Hope on Wheels will travel to all 68 Hope Grant recipients to present the donations and hear from children, their families and all of those involved in the fight against cancer.

“While we’ve made progress over the last few decades and now have an 85 percent cure rate, cancer still takes more lives than any other childhood disease,” said John Krafcik, President and CEO of Hyundai Motor America. “This September, in support of Childhood Cancer Awareness Month, Hyundai will shine a nationwide spotlight on this cause and provide more than $6 million in grants for pediatric cancer research and support programs. We love taking on big challenges at Hyundai, and we can think of no more worthy challenge than finding a cure for all forms of pediatric cancer.”

Located in Maine’s scenic Sebago Lake region, Camp Sunshine features a 23-acre lakeside campus with private family suites, as well as a climbing wall, indoor swimming pool and computer learning center — all of which are free of charge to all families. To date, Camp Sunshine has welcomed families from 47 states and 17 countries.

“Camp Sunshine is delighted and humbled to receive this generous donation from Hyundai,” said Matt Hoidal, executive director, Camp Sunshine. “This investment will enable us to expand our programs in 2011 and bring nearly 1,000 children and their families much needed respite, support, and hope. We thank Hyundai and their network of dealers in Northern New England and around the country for helping us continue our service and contributions to the cancer community.”

About Camp Sunshine
Camp Sunshine offers children with life-threatening illnesses and their families a place to relax together for a week, and to take a break from the extraordinary demands placed upon them on a daily basis. The year-round program is free of charge and staffed almost entirely by volunteers. It is the only program in the nation whose mission is to address the impact of a life-threatening illness on every member of the immediate family — the ill child, the parents and the siblings. Since its inception in 1984, Camp Sunshine has provided a haven for more than 32,000 individuals from diverse cultural backgrounds. In addition to providing 24-hour on-site medical and psychosocial support, the camp offers a variety of daily activities, including swimming, boating, archery and soccer, and special events such as bonfires and cookouts. To support Camp Sunshine, please call (207) 655-3800 or visit www.campsunshine.org.

About Hyundai Motor America
Hyundai Motor America, headquartered in Fountain Valley, Calif., is a subsidiary of Hyundai Motor Co. of Korea. Hyundai vehicles are distributed throughout the United States by Hyundai Motor America and are sold and serviced through more than 800 dealerships nationwide.

About Hyundai Hope on Wheels
Hyundai Hope on Wheels™ is the united effort of more than 800 Hyundai dealers across the U.S. to raise awareness about childhood cancer and celebrate the lives of children battling the disease. By the end of 2010, Hope on Wheels will have awarded more than $23 million dollars to children’s hospitals and non-profit organizations across the U.S. to support the fight against childhood cancer.

LONDON–(Marketwire – September 2, 2010) –  Genome Research Group (GRG) (PINKSHEETS: KKUR) recently announced its intended merger with ChromoCure, Inc. and consolidation of the operations and technologies of both groups. Genome Research Group personnel have assumed all executive and board duties and have no current or planned operations in the USA.

The company intends to open permanent offices in the United Kingdom as well as establish the first of several planned research labs and testing partners.

To date, the Company has not been able to secure its previously anticipated investment capital due to the declining USA economy and capital markets. The Company believes it has now secured satisfactory capital commitments and will proceed with its business plan accordingly.

The Company’s objectives are:

1. Recapitalize the company’s stock structure and change the company’s trading symbol to trade under “Genome Research Group.”

2. Establish business offices and permanent address in the United Kingdom with the most likely location being London.

3. Structure the company’s operations as decentralized management with multiple operational hubs and team members around the world.

4. Secure initial research lab space for the Company’s ongoing research and development for both its cancer imaging systems as well as its therapeutic protocols and animal modeling experiments.

5. Appoint industry leaders to the Company’s Board of Advisors.

6. Partner with cancer labs and pathology labs within the European Union. The Company does not believe the USA healthcare market will be an open market inviting of innovation or new ideas. The Company has no immediate plans to seek partnerships within the USA due to healthcare over-regulation and control by the US government.

7. Complete and deploy company branding, image, and professional design of marketing and educational materials.

8. File updated financial information with appropriate legal opinion letter to achieve “Current” reporting status. The Company has no immediate intent to become a “SEC Reporting” company due to the massive expense and liability of that status.

The Company intends to release updates from time to time as these actions are completed.

About Genome Research Group
Genome Research Group develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company’s proprietary cancer detection system locates and measures unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s proprietary Therapeutic Modeling Protocols provide statistical modeling and prediction tools for the measurement and monitoring of cancer progression and remission. GRG owns proprietary techniques for non-toxic and non-invasive cancer therapy utilizing hypothermic modulation and resonance.

Safe-Harbor Statement
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

CENTERVILLE, MA–(Marketwire – September 1, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) announced today that the improved features added to its UV-400 air purifier have been generating a surprising amount of interest from distributors.

The Company recently began coating the inside of its patented UV-400 cartridge with a thin layer of the photo-catalyst Titanium Dioxide (TiO2). Combined with the germicidal UV lamps contained within the cartridge, and moisture in the air, the hydroxyl radicals produced by the TiO2 accelerate the breakdown of molecular bonds present as odors or in the case of Volatile Organic Compounds (“VOC”). These compounds are converted into harmless water vapor and carbon dioxide, which results in significantly reducing the concentration and effects of odors and VOC’s.

“Volatile Organic Compounds, such as acetone, formaldehyde, benzene, as well as hundreds of other compounds, are surprisingly common in offices or households, and can be harmful in even small concentrations to people with respiratory problems, especially children and the elderly,” stated Jack Lennon, President of UV Flu Technologies. “Carpets, building materials, cleaning supplies, paints and varnishes, vinyl floors and furniture, air fresheners, copiers and printers, pesticides, secondhand smoke, wood burning stoves, nail polish remover and hair products; are all just a small sample of the products emitting VOC’s, many of which cause allergic reactions, as well as many of them containing known carcinogens. The UV-400 product has undergone laboratory tests which show the concentration of VOC’s are reduced significantly with each pass, which is repeated several times per hour in a typical room.”

“Many of our customers are very excited about this feature,” commented Bill Fegley, President of Puravair, a major distributor of UV Flu products. “The reduction of the concentration of these compounds and odors is considered very important to a wide array of our customer base, such as salons, health clubs, funeral homes, restaurants and athletic facilities. This feature, combined with the UV-400’s proven ability to kill bacteria, make it a compelling purchase for any location that commonly finds these types of airborne contaminants present in the course of their day-to-day operations.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – August 27, 2010) –  The economy of Mexico is challenged by a recession, oil prices, and a falling exchange rate. Yet according to a new report from healthcare market research publisher Kalorama Information, Mexico is still attracting clinical diagnostic companies and showing modest growth. Mexico’s IVD market grew 75% between 2004 and 2009, according to the report “McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico,” which is a joint publication of Kalorama and emerging IVD market research firm McEvoy and Farmer.

Mexico followed the United States into recession, which has hurt the private side of the in vitro diagnostic market, according to the report. Most diagnostic tests in Mexico are publicly-funded, but the report notes there may be a strain on finances next year due to the fall in the price of oil and an impending budget deficit. The exchange rate has changed from 10.9 pesos per dollar in 2007 to the current level of nearly 13; a sixteen-percent decline over the past two years. 

“The fall of the peso hurts because most IVD products are not manufactured in Mexico,” said Bruce Carlson, Publisher of Kalorama Information. “Still, the analysts see a good number of top-level manufacturers here, and they are betting that when the US comes out of recession, Mexico will follow.”

In the report, Kalorama Information and McEvoy and Farmer detail 18 manufacturers and 30 distributors that are currently competing in Mexico’s IVD market, including Abbott, BD and Bio-Rad.

“McEvoy and Farmer’s Complete Guide to IVD Distribution in Mexico” provides more information, including healthcare statistics, market size numbers for segments of the IVD market and information about distributors and what products they distribute in Mexico. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79516&productid=2768446

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).